DANIEL ERNESTO
CASTELLANO GAUNA

Profesor asociado

Foto de DANIEL ERNESTO

Foto de Helsinki University Central Hospital

Helsinki University Central Hospital

Helsinki, Finlandia

Publications en collaboration avec des chercheurs de Helsinki University Central Hospital (6)

2024

Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10)
Urologic Oncology: Seminars and Original Investigations
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
European Urology

2020

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial
Cancer, Vol. 126, Núm. 18, pp. 4156-4167

2018

Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962–71] (S0302283817300994) (10.1016/j.eururo.2017.02.010))
European Urology

2017

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma [Figure presented]
European Urology, Vol. 72, Núm. 6, pp. 962-971

2015

Nivolumab versus everolimus in advanced renal-cell carcinoma
New England Journal of Medicine, Vol. 373, Núm. 19, pp. 1803-1813